Zacks Research Upgrades Omnicell (NASDAQ:OMCL) to “Hold”

Omnicell (NASDAQ:OMCL) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Omnicell’s Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.29 EPS and Q3 2027 earnings at $0.28 EPS.

A number of other research analysts have also issued reports on the company. Wells Fargo & Company boosted their target price on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Weiss Ratings downgraded Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research report on Wednesday, January 7th. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Benchmark upped their price objective on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.50.

Omnicell Price Performance

Shares of OMCL opened at $37.48 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The firm has a 50-day simple moving average of $44.18 and a 200-day simple moving average of $38.44. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of 937.23, a price-to-earnings-growth ratio of 1.40 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The company had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities research analysts anticipate that Omnicell will post 1.09 earnings per share for the current year.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OMCL. Wellington Management Group LLP lifted its holdings in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after acquiring an additional 1,265,818 shares during the period. Millennium Management LLC purchased a new position in shares of Omnicell in the 3rd quarter valued at about $25,625,000. Boston Partners acquired a new stake in shares of Omnicell in the fourth quarter valued at about $20,805,000. Two Sigma Investments LP lifted its stake in shares of Omnicell by 93.8% in the third quarter. Two Sigma Investments LP now owns 559,969 shares of the company’s stock valued at $17,051,000 after purchasing an additional 271,008 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Omnicell by 9.1% during the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after buying an additional 197,462 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.